Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma

Table 1 Associations and comparisons between phosphatidylinositol 3-kinase CB expression and clinicopathological factors in 208 rectal adenocarcinoma patients receiving preoperative radiotherapy

Parameter		No. of cases	PIK3CB expression		P value
			Low	High
Sex	Male	120	37	83	0.619
	Female	88	30	58
Age in years	< 65	140	47	93	0.547
	≥ 65	68	20	48
TH in cm	< 5	74	14	60	0.002
	≥ 5	134	53	81
PreTNM	II	29	9	20	0.945
1(18)	III	161	51	110
BMI	0	11	2	9	0.300
	1	105	29	76
	2	76	29	45
	3	16	5	11
LVI	Negative	21	4	17	0.222
	Positive	187	63	124
Diff.	ypCR	11	3	8	0.562
1(1)	G1-2	146	41	105
	G3-4	50	18	32
ypT	T0	8	6	2	0.043
	T1	11	4	7
	T2	55	20	35
	T3	134	37	97
ypN	N0	122	36	86	0.608
	N1	55	20	35
	N2	31	11	20
TRG	1 (G1-2)	32	29	3	0.000
	2 (G3)	79	26	53
	3 (G4-5)	97	12	85

¹Lack of number of patients. 0: < 18.4; 1: 18.5-23.9; 2: 24.0-27.9; 3: ≥ 28.0. TH: Tumor height; BMI: Body mass index; PIK3: Phosphatidylinositol 3-kinase; LVI: Lymph vessel invasion; TRG: Tumor regression grade.

Table 2 Univariate log-rank analysis for important clinicopathological and phosphatidylinositol 3-kinase CB expression

Parameter	DSS			LRFS			MeFS
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
Sex	1.482	0.654-3.356	0.346	0.970	0.483-1.945	0.931	0.586	0.219-1.570	0.288
Age	0.908	0.377-2.186	0.830	1.491	0.749-2.970	0.25602	1.947	0.808-4.693	0.138
TH	0.737	0.320-1.698	0.473	1.096	0.412-2.915	0.854	0.726	0.218-2.413	0.601
PreTNM	0.976	0.309-3.084	0.967	0.809	0.293-2.237	0.683	0.507	0.145-1.771	0.287
BMI	1.385	0.774-2.480	0.272	1.180	0.732-1.903	0.497	1.106	0.569-2.151	0.766
LVI	2.018	0.687-5.927	0.202	1.106	0.366-3.340	0.858	0.851	0.214-3.376	0.818
Diff.	1.065	0.470-2.415	0.880	0.460	0.203-1.041	0.062	0.438	0.128-1.494	0.187
ypT	1.200	0.546-2.640	0.650	0.971	0.537-1.756	0.923	1.067	0.488-2.332	0.872
ypN	0.839	0.498-1.414	0.510	2.926	1.816-4.713	0.000	2.442	1.275-4.674	0.007
TRG	2.337	1.064-5.136	0.035	1.981	1.012-3.877	0.046	2.755	1.052-7.215	0.039
PIK3CB	1.685	0.727-3.909	0.224	2.228	0.801-6.202	0.125	1.828	0.397-8.411	0.439

DSS: Disease-specific survival; LRFS: Local recurrence-free survival; MeFS: Metastasis-free survival; PIK3: Phosphatidylinositol 3-kinase; TH: Tumor height; BMI: Body mass index; LVI: Lymph vessel invasion; TRG: Tumor regression grade.

Table 3 Multivariate analysis for important clinicopathological and phosphatidylinositol 3-kinase CB expression

Parameter			DSS		LRFS		MeFS
		No. c	No. e	P value	No. e	P value	No. e	P value
Sex	Male	120	43	0.554	109	0.476	90	0.109
	Female	88	27		86		64
Age in years	< 65	140	49	0.769	130	0.502	99	0.173
	≥ 65	68	21		65		55
TH in cm	< 5	74	28	0.053	66	0.072	56	0.004
	≥ 5	134	42		129		98
PreTNM	II	29	7	0.544	27	0.959	23	0.437
	III	161	581 (5)		1481 (20)		1151 (16)
BMI	0	11	5	0.008	11	0.628	6	0.906
	1	105	29		96		84
	2	76	31		72		52
	3	16	5		16		13
LVI	Negative	21	11	0.506	19	0.647	12	0.115
	Positive	187	59		176		142
Diff.	ypCR	11	11 (1)	0.189	111 (1)	0.974	10	0.951
	G1-2	146	48		139		108
	G3-4	50	20		44		36
ypT	T0	8	1	0.359	8	0.374	8	0.544
	T1	11	4		11		8
	T2	55	8		54		48
	T3	134	57		122		90
ypN	0	122	25	0.043	116	0.000	103	0.005
	1	55	24		52		34
	2	31	21		27		17
TRG	1 (G1-2)	32	5	0.020	31	0.018	28	0.021
	2 (G3)	79	25		77		56
	3 (G4-5)	97	40		87		70
PIK3CB	Low exp	67	19	0.124	62	0.011	51	0.010
	High exp	141	51		133		103

¹Lack of number of patients. DSS: Disease-specific survival; LRFS: Local recurrence-free survival; MeFS: Metastasis-free survival; PIK3: Phosphatidylinositol 3-kinase; TH: Tumor height; BMI: Body mass index; LVI: Lymph vessel invasion; TRG: Tumor regression grade.